Sarcoidosis. Organ involvement, diagnosis, current treatment

被引:0
作者
Weidenthaler-Barth, B. [1 ]
Steinbrink, K. [1 ]
Kuemmel, A. [2 ]
von Stebut, E. [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Hautklin Univ Med Mainz, D-55122 Mainz, Germany
[2] Univ Med Mainz, Med Klin 3, Pneumol, Mainz, Germany
来源
HAUTARZT | 2015年 / 66卷 / 07期
关键词
T-cells; Granuloma; Lung involvement; Adenopathy; Immunosuppression; CUTANEOUS SARCOIDOSIS; THERAPY; CHLOROQUINE;
D O I
10.1007/s00105-015-3646-5
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Sarcoidosis is characterized by the appearance of noncausating, epitheloid cell granulomas, primarily in skin and lung. Hereditary disposition is well known; additional infection-associated triggers play a role for the development of inflammation mediated by T helper (Th) 1 cells. Clinically, various disease courses can be observed that are characterized by the formation of skin papules at typical sites of the body which differ in their tendency to be associated with systemic organ involvement. Systemic disease without skin affections is also possible. The diagnosis is based on the typical clinical appearance, biopsy of affected tissue (e.g. skin, lung) and laboratory investigations. Additional systemic involvement needs to be excluded. In most cases, the disease is self-limited, but can also be life threatening due to organ fibrosis. The degree of (extra-) cutaneous involvement and level of discomfort are used to select the type of treatment, which ranges from topical immune suppressive agents to systemic therapy with corticosteroids. In nonresponders, additional modern immunosuppressive/immunomodulating therapeutic options are available.
引用
收藏
页码:549 / 561
页数:13
相关论文
共 23 条
[1]  
Altmeyer P, DERMATOLOGIE VENEROL
[2]   Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement [J].
Baughman, Robert P. ;
Drent, Marjolein ;
Kavuru, Mani ;
Judson, Marc A. ;
Costabel, Ulrich ;
du Bois, Roland ;
Albera, Carlo ;
Brutsche, Martin ;
Davis, Gerald ;
Donohue, James F. ;
Mueller-Quernheim, Joachim ;
Schlenker-Herceg, Rozsa ;
Flavin, Susan ;
Lo, Kim Hung ;
Oemar, Barry ;
Barnathan, Elliot S. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (07) :795-802
[3]   Clinical characteristics of patients in a case control study of sarcoidosis [J].
Baughman, RP ;
Teirstein, AS ;
Judson, MA ;
Rossman, MD ;
Yeager, H ;
Bresnitz, EA ;
DePalo, L ;
Hunninghake, G ;
Iannuzzi, MC ;
Johns, CJ ;
McLennan, G ;
Moller, DR ;
Newman, LS ;
Rabin, DL ;
Rose, C ;
Rybicki, B ;
Weinberger, SE ;
Terrin, ML ;
Knatterud, GL ;
Cherniak, R .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (10) :1885-1889
[4]   Presenting characteristics as predictors of duration of treatment in sarcoidosis [J].
Baughman, RP ;
Judson, MA ;
Teirstein, A ;
Yeager, H ;
Rossman, M ;
Knatterud, GL ;
Thompson, B .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2006, 99 (05) :307-315
[5]   A clinical approach to the use of methotrexate for sarcoidosis [J].
Baughman, RP ;
Lower, EE .
THORAX, 1999, 54 (08) :742-746
[6]   INTRA-LESIONAL CORTICOSTEROIDS [J].
CALLEN, JP .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1981, 4 (02) :149-151
[7]  
Costabel U, 2014, KARDIOLOGE, V8, P13, DOI 10.1007/s12181-013-0550-z
[8]  
Crommelin HA, 2014, IMMUNOTHERAPY-UK, V6, P1127, DOI [10.2217/IMT.14.65, 10.2217/imt.14.65]
[9]   Evidence-based therapy for cutaneous sarcoidosis [J].
Doherty, Christy B. ;
Rosen, Ted .
DRUGS, 2008, 68 (10) :1361-1383
[10]  
Fauci AS, 2009, HARRISONS INNERE MED